Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
11 evidence topics · 17 sources
Pooled effect of psilocybin-assisted therapy in meta-analyses of randomized trials
“The pooled SMD for 1-week between-group change in depression ratings was -0.72 [95% CI, -0.95 to -0.49; I2 = 17%; 5 RCTs; n = 403], favouring PAT; results were similar at days 2, 14, and 42.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response [RR = 3.42; 95% CI, 2.35-4.97; I2 = 0%; 4 RCTs; n = 373] and remission [RR = 3.66; 95% CI, 2.26-5.92; I2 = 0%; 4 RCTs; n = 373] rates also favored PAT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Within-group change in psilocybin, SSRI, and esketamine trials
“Pretreatment to posttreatment SMCs (SEMs) were 1.21 (0.15) for psilocybin, 1.28 (0.06) for SSRIs, and 1.43 (0.15) for esketamine and were 0.50 (0.15), 1.00 (0.08), and 1.12 (0.17) for their respective control treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative effect compared with escitalopram in a network meta-analysis
Phase 2b trial: response, remission, and sustained response after a single 25 mg dose
“In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability after a single dose over 52 weeks
“For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported response, remission, and durability with retreatment
Independent phase 2b trial in treatment-resistant depression with an active placebo
“Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world outcomes outside controlled trials
“Response and remission rates were 33.3% and 22.2% (MADRS), and 27.8% and 27.8% (BDI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin was associated with a clinically meaningful reduction in depressive symptoms, with response and remission rates below those reported in previous trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term outcomes in veterans with severe treatment resistance
“At Month 12, 40 % maintained response and 30 % maintained remission.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the antidepressant effects began to wane at 6 months, and then more substantially after 9 months, although these increases in MADRS did not reach statistical significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory statement on the evidence for durability and retreatment
Expected outcomes with further conventional treatment steps or usual care
“The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote